Cefepime for Gram-Negative Rod Infections

Effectiveness Against Specific Gram-Negative Pathogens

• For Enterobacteriaceae infections, cefepime has shown efficacy comparable to ceftriaxone and ertapenem in treating community-acquired pneumonia 1
• For Klebsiella pneumoniae infections, ertapenem has shown equivalent efficacy to cefepime in treating pneumonia with Enterobacteriaceae infection 1

ESBL-Producing Organisms

• For ESBL-producing Enterobacteriaceae, carbapenems (imipenem or meropenem) are recommended as first-line therapy for severe infections and bacteremia 2, 3

Carbapenem-Resistant Organisms

• For carbapenem-resistant Enterobacteriaceae (CRE), newer agents like meropenem-vaborbactam or ceftazidime-avibactam are preferred over cefepime for severe infections 4
• For carbapenem-resistant Pseudomonas aeruginosa (CRPA), ceftolozane-tazobactam is suggested if active in vitro 4

Combination Therapy Considerations

• For complicated intra-abdominal infections, cefepime must be combined with metronidazole for anaerobic coverage 5
• For Pseudomonas aeruginosa infections, two antipseudomonal antibiotics may be empirically used initially due to the risk of resistance to a single agent 1

Antimicrobial Stewardship Considerations

• To preserve carbapenems, cefepime may be used as a carbapenem-sparing option for susceptible organisms 6
• The use of cephalosporins should be limited in settings with high incidence of ESBL-producing Enterobacteriaceae due to selection pressure resulting in emergence of resistance 6
• Obtaining microbiological cultures before initiating therapy is recommended to guide targeted treatment and allow for de-escalation when appropriate 5

Important Caveats and Pitfalls

• For severe infections with ESBL-producing organisms, carbapenems remain the treatment of choice due to more reliable clinical outcomes 2